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Abstract: Despite the increasing number of older people, many with cognitive impairment (CI),
in hospitals, there is yet to be an evaluation of hospital-wide interventions improving the management
of those with CI. In hospitalized patients with CI, there are likely to be associations between increased
complications that impact on outcomes, length of stay, and costs. This prospective study will evaluate
the effectiveness of an established hospital CI support program on patient outcomes, patient quality
of life, staff awareness of CI, and carer satisfaction. Using a stepped-wedge, continuous-recruitment
method, the pre-intervention patient data will provide the control data for usual hospital care.
The intervention, the Dementia Care in Hospitals Program, provides hospital-wide CI awareness and
support education, and screening for all patients aged 65+, along with a bedside alert, the Cognitive
Impairment Identifier. The primary outcome is a reduction in hospital-acquired complications:
urinary tract infections, pressure injuries, pneumonia and delirium. Secondary outcome measures
include cost effectiveness, patient quality of life, carer satisfaction, staff awareness of CI, and staff
perceived impact of care. This large-sample study across four sites offers an opportunity for
research evaluation of health service functioning at a whole-of-hospital level, which is important for
sustainable change in hospital practice.
Keywords: delirium and cognitive disorders; acute hospital; nursing; nonclinical staff dementia;
education; cost and cost analysis; system redesign
1. Introduction
Dementia is the leading cause of disability burden and the second leading cause of burden of
disease for people aged 65+ [1]. Eighty-three-thousand patients with dementia are admitted to hospital
each year in Australia [1].
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People with dementia experience poorer outcomes of hospitalization, including higher rates
of hospital-acquired complications [2]; higher rates of discharge to residential care [3]; higher
morbidity [4]; and more bed days in hospital [5]. Outcome measurement is hampered by difficulty in
relying on documentation of dementia diagnosis as it often goes undetected and, if detected, often
goes undocumented [6].
In complex hospital environments, the diagnosis and documentation of dementia is made difficult
by the presence of other causes of memory and thinking disorders, such as delirium, head injury,
or narcosis. These disorders can be symptomatically similar to dementia regarding presentation of
confusion and disorientation. The higher risks of hospital-acquired complications documented in
people with dementia [2] could also be associated with these “failures in cognition”. Consequently,
the term ‘cognitive impairment’ (CI) can be used to describe the memory and thinking difficulties seen
in hospital without ascribing a diagnosis. CI is increasingly used as a term to encompass the breadth
of disorders causing brain dysfunction, and in hospitals is most likely caused by dementia, delirium or
stroke [7].
Adults admitted to Australian hospitals are assumed to have the cognitive capability to respond
to the demands of hospital care, which require information retention, dexterity, insight and empathy.
Some hospital safety systems, such as medication safety, rely on this cognitive ability in order to be
effective [8]. It is estimated, however, that 30% of patients aged 65+ have CI during their hospital
stay [7]. While dementia is the focus of much of the current research related to risks of hospitalization,
this study will target patients with CI, who are likely to share similar high levels of risk.
Risk of hospitalization for patients with CI is compounded by the complexity of the hospital
environment. Hospital staff are known to be inadequately equipped to identify, or respond
appropriately to, people with dementia or other cognitive impairments [7]. Staff report difficulty in
engaging with patients with CI and their families [9], and that older people’s needs may not align well
with the acute hospital setting [10]. Patients with CI require higher support needs for communication,
procedural interventions, ambulation, toileting, and medication administration [11]. Positive nursing
work environments with manageable workloads [12–14], and acute models for the care of older people,
have been associated with lower rates of hospital-acquired complications [15,16], indicating that, with
suitable models of care, these are potentially modifiable patient outcomes.
Risk screening combined with appropriate mitigation processes on admission to hospital is
a well-recognized approach to identify and reduce patient risk [17]. Similarly, screening for CI
provides an opportunity for follow-up interventions and the implementation of appropriate care.
Following up an effective screening program with a process for hospital-wide awareness of patients
with CI, embedded by way of a simple staff–patient communication strategy, has the potential to
reduce incidence of complications, improve hospital outcomes, reduce length of stay, and lower costs.
The Dementia Care in Hospitals Program (DCHP) provides an intervention that aims to change
the hospital care paradigm from one where all hospitalized adults are expected to manage the complex
demands of hospital care, to one where it is recognized that additional support and a change to the
hospital processes and environment are needed for those with CI.
The DCHP is a hospital-based education and system-change program linked to screening
for CI. Unlike dementia diagnosis, screening for CI does not require complex algorithms: it is a
functional descriptor of impairment of memory and thinking associated with risk. Analogous to falls,
the identification of this sort of functional risk can be embraced by nursing and allied health staff.
Previous evaluation of the program showed improvements in staff knowledge, confidence and
comfort in dealing with patients with CI [9], and increased carer satisfaction [18]. The effect of the
program on clinical outcomes, patient quality of life, and cost effectiveness has, however, not yet
been measured.
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Study Aim and Hypotheses
The primary aim of this hospital-based interventional study is to determine if the DCHP will
reduce hospital-acquired complications in people aged 65+ with CI, compared to those receiving
usual hospital care. Secondary aims include an economic evaluation of the intervention compared to
usual hospital care, and an examination of its impact on patient quality of life, carer satisfaction, staff
awareness of CI, and staff perceived burden of care when caring for patients with CI in hospital.
2. Materials and Methods
2.1. Study Design and Setting
The impact evaluation of the DCHP will use a prospective, stepped-wedge, cross-sectional,
continuous-recruitment study design. Patients aged 65+ will be screened for CI within 24 h of
hospital admission and included if they have CI. Recruitment will occur continuously over the
study period, with individual patients remaining in the study for the length of their hospital stay.
Patients aged 65+ admitted to the target wards of a single hospital are referred to as a cluster; there
will be four clusters across four Australian jurisdictions. Three sites are large metropolitan hospitals
with a university affiliation; and one is a regional hospital. At each hospital, the wards selected to
implement the DCHP will be determined by level of interest from the nursing leadership team and
a requirement for a spread of wards across medical, surgical, and acute aged care. The Baseline
period was determined by the estimated time required to achieve 80% patient screening and 40% staff
education. The 42-week intervention period was considered sufficient time for change to be measurable
within the constraints of the project funding. Consistent with a stepped-wedge trial design [19], each
cluster provides both before and after observations, and clusters incrementally shift from control to
intervention (see Table 1—Stepped-Wedge Timeline). Hospital-acquired complications data will be
analyzed cross-sectionally.
2.2. Study Population
The participant pool will comprise all patients aged 65+ (50+ for those identifying as Aboriginal
and Torres Strait Islander) admitted for more than 24 h to participating wards and screened for
CI using a validated screening tool. There will be no patient exclusions. Patients transferred
between participating wards will be counted once. Patients transferred to a participating ward
from a nonparticipating ward will be included if they stay on the participating ward for longer than
24 h, and patients transferred from a participating ward on which they had stayed for greater than
24 h to a nonparticipating ward will also be included. Consent was confirmed with each participating
health service via waiver of consent documentation.
The Dementia Quality of Life Measure (DemQol) and Carer surveys will be completed by a subset
of the participant pool who screen positive for CI, and their carers. Staff surveys will be completed by
personnel on the relevant wards who have regular contact with the target patient group. These will
include clinical (nursing, medical and allied health) and nonclinical staff (ward clerks, food and
domestic staff, porters and cleaners) on the participating wards.
2.3. Materials
The choice of screening tool was determined by the hospitals at the time of site selection. It was
requested that a validated screening tool be used, and hospitals chose tools that were already embedded
in current practice. Criteria and screening tools for CI and study inclusion are presented in Table 2.
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Table 1. Stepped-Wedge Timeline.
Timeline February 2014 toFebruary 2015 March 2015 June 2015
September
2015
December
2015 March 2016
May
2016
July
2016
September
2016
December
2016
February
2017
Weeks 52 12 12 12 12 12 12 12 12 12 12
1 BL1 NormalPractice
BL1 Normal
Practice
BL2
Training
BL2
Training T1 T2 T3 T4 T5
2 BL1 NormalPractice
BL1 Normal
Practice
BL1 Normal
Practice
BL2
Training
BL2
Training T1 T2 T3 T4 T5
3 BL1 NormalPractice
BL1 Normal
Practice
BL1 Normal
Practice
BL1 Normal
Practice
BL1 Normal
Practice
BL2
Training T1 T2 T3 T4 T5
4 BL1 NormalPractice
BL1 Normal
Practice
BL1 Normal
Practice
BL1 Normal
Practice
BL1 Normal
Practice
BL1 Normal
Practice
BL2
Training T1
T2 T3 T4
BL1 = Normal Practice; BL2 = Baseline / Training Phase (yellow); T1–T5 = Intervention phases (green).
Table 2. Cognitive Impairment Screening Tools.
Tool Abbreviation Criteria for Positive CI Screen Used by Site Reference
Abbreviated Mental Test AMT Score≤ 7 1 Hodkinson [20]
Mini-Cog Recall 1 or 2 of 3 items and abnormal ClockDrawing; or recall of 0 of 3 words. 4 Borson [21]
Abbreviated Mental Test Score
4 * AMT4 Score of 3 or less 2 and 3 Swain [22]
Clock Drawing Test ˆ CDT Not all clock numbers present, spaced unevenly, orhands pointing to incorrect time. 2, 3 and 4 Scanlan [23]
* Only used in conjunction with Clock Drawing Test (CDT); ˆ used in conjunction with either AMT4 or MiniCog.
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Each hospital will receive face-to-face and remote support from the DCHP National
Implementation Team based at Ballarat Health Services. Project implementation will support a
full-time on-site project officer, materials, and travel funding. The implementation team will visit each
site for a project launch and education session. Local education will be supported by the project officer
and provision of an education package that is appropriate for both clinical and nonclinical staff.
2.4. Data
Hospital-acquired complication data will be drawn from routinely collected hospital data sets and
submitted to the Health Roundtable (HRT) [24], which is a not-for-profit membership organization
of participating hospitals across Australia and New Zealand. HRT holds routinely collected data for
8 years for all the hospitals in the DCHP. The hospital-acquired complications for the evaluation were
derived from hospital-coded patient records. This method is based on work by Needleman et al. [12],
and updated to ICD10 by Bail et al. [2]. All the diagnostic codes for the patients’ episodes will be
examined separately. Patients with at least one of four complications will be recorded as positive for a
hospital-acquired complication.
Staff surveys, carer surveys and patient DemQoLs [25,26] will be collected during the
pre-intervention period and at approximately six months post-intervention.
Ethics approval has been obtained for data sharing with the external evaluation team. Patient data,
which will be de-identified prior to analysis, will include patient descriptors (e.g., age, name,
Unit Record Number (UR), Aboriginal and Torres Strait Islander (ATSI) status, comorbidity index),
and episode descriptors (e.g., length of stay, discharge ward).
Data will be stored on a secure server with restricted access. Data will be entered into Excel
spreadsheets on-site and at the DCHP National Office for later analysis using the SPSS and Stata
statistical software packages. To ensure data integrity, all data cleaning and data entry will be
completed by two research assistants using a cross-check methodology. Responsibility for appropriate
and secure data storage rests with the primary investigator and the evaluation team.
2.5. Outcome Measures
The primary outcome measure will be the change in the rate of the combined risk of one
or more of the following hospital-acquired complications: urinary tract infection, pressure injury,
pneumonia or delirium before and after the adoption of the DCHP. The rate of this combined risk will
be determined for patients who screen positive for CI over a 12-week period before the introduction of
the DCHP, and for patients who screen positive for CI over four consecutive 12-week periods during
implementation. A summary of primary and secondary outcomes as well as relevant instruments
and sources is provided in Table 3. Falls rates will be a secondary outcome as per Medibank Private
methodology, using the Y9222 flag within the ICD code to indicate whether a fall occurred in hospital
or not [27].
Table 3. Outcome measure, instruments and data sources.
Outcome Measure Instrument/Source
Primary Outcome: Clinical
The change in the rate of the combined risk of
one or more of the hospital-acquired
complications: urinary tract infection, pressure
injury, pneumonia and delirium, before and
after the adoption of the DCHP.
Health Roundtable [24]
Primary Outcome: Cost
Difference in mean total cost of hospitalization
for patients aged 65+ before and after the
adoption of the DCHP.
Difference in mean total cost of hospitalization
for patients aged 65+ who screen positive for CI
before and after the adoption of the DCHP.
Health Roundtable [24]
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Table 3. Cont.
Outcome Measure Instrument/Source
Secondary Outcome: Cost
Effectiveness
Quality of life
Length of stay
Cost effectiveness
DemQol ˆ [25,26]
Health Roundtable [24]
Secondary Outcome:
Satisfaction/Confidence
Staff knowledge and confidence
Carer satisfaction
Staff survey # (see
Supplementary Materials S1 & S3)
Carer survey # (see
Supplementary Materials S2 & S4)
Secondary Outcome: Medication
and Patient Safety
Total antipsychotic usage per admission
Anticholinergic load per admission [28]
In-hospital falls and mortality
Medical Record review
Health Roundtable [24]
Secondary Outcome:
Sustainability
The rate of the combined risk of one or more of:
urinary tract infection, pressure injury,
pneumonia and delirium in patients 65+ with
CI occurring during the hospital admission.
Health Roundtable [24]
# Both surveys have been developed for the Dementia Care in Hospitals Program (DCHP, https://www.bhs.org.
au/node/130) and used across all 25 rollouts. The questions target key education goals including changes to staff
attitudes and actions. Attached as Supplementary Materials; ˆ DemQol [25,26] will be used for patients who screen
positive for Cognitive Impairment (CI).
2.6. Intervention
2.6.1. DCHP Implementation, Hospital Engagement and Ward Delivery
The DCHP includes a whole-of-hospital communication training program for all staff. Other key
components are the development of hospital-specific clinical pathways (protocols, policies), executive
management support, and ward-based ‘champions’ for the identification and management of CI.
The DCHP also requires close engagement with carers/family of patients with CI. The primary
vehicle for the program’s hospital engagement is an easily recognizable bedside alert: the ‘Cognitive
Impairment Identifier’ (CII—see Figure 1).
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The education and training sessions are aimed at enabling staff to better understand, and work
with, patients with CI and their carers/family. Initial training of the local teaching staff will be
conducted by the DCHP National Implementation Team. It is anticipated that, during implementation,
the education program will be delivered to 80% of all staff with patient contact on target wards.
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Cross-over from Baseline to Intervention will not occur until a minimum of 40% of target staff have
received training.
2.6.2. Measures of Successful Implementation and Confounders
Successful adoption of the DCHP will have significant influence on the results of the evaluation.
Target ward screening rates will be collected monthly. It is anticipated that 100% of patients aged 65+
will be screened and the CII used for 80% of those who screen positively. Staff education rates will be
monitored to ensure a sustained rate of 80% over the 12 months of the program.
2.6.3. Intervention Costs
The resources used in the intervention will be fully costed and attributed to the inpatient
population aged 65+ in the relevant wards. This includes the cost of developing the training package,
staff training costs (time), and the time taken to conduct screening. The cost of the training package
will be treated as a capital cost with an allowance made for periodic updates. Costs attributable to
evaluation will not be included in the cost analysis.
2.6.4. Blinding
Blinding will not occur, as there is no practical way to blind hospital staff or members of the
evaluation teams.
2.6.5. Sample Size, Power Calculation and Analysis
Based on a conservative estimate of 750 positive screens for CI in each period, the target sample
size is a total of 3750 patients. The required sample has been calculated with power 0.8, type I error
0.05 and design effects based on clustering effect (ICC) at site (0.05) level. It is estimated that for
a complication rate ranging from 20–26%, this sample size will enable detection of a 22–25.5% or
more reduction in risk ratio (RR). This is equivalent to a minimum 5–5.5% reduction in absolute risk.
A generalized linear mixed model for a binary outcome with time epoch as a fixed factor and hospitals
as a random effect for an incomplete stepped-wedge design with a cross-sectional design was adopted
for the power calculation [29]. Stata software was used for this purpose [30].
In relation to the secondary outcomes, based on type I error of 0.05 and a power of 0.9, a target
sample size of 160 DemQols per site (80 at baseline and 80 at intervention) is required to detect 15-point
differences in health-related quality-of-life score.
Assuming a type I error of 0.05 and a power of 0.8, a target sample size of 140 carer surveys (70 at
baseline and 70 at intervention) is required to detect a minimum effect size of 0.4.
2.6.6. Ethics Approval
The study protocol has been approved by the relevant Ethics Committee at each site.
Ethics approval numbers are as follows: HREC/15/TQEH/9 (Government of South Australia,
SA Health, Human Research Ethics Committee); ETH.6.15.105 (ACT Health, Human Research Ethics
Committee); HREC/15/TQEH/9 (Human Research Ethics Committee (Tasmania) Network); 2015-103
(Government of Western Australia, Department of Health, Human Research Ethics Committee).
The Registration Number is Australian New Zealand Clinical Trials Registry (ANZCTR)
ACTRN12615000905561.
3. Discussion
A stepped-wedge design is a logical fit, given that hospitals are constantly changing their care
models in different ways and across varying time courses. The stepped-wedge methodology is
designed to control for potential bias that occurs as a result of variations in hospital practice and the
introduction of new regulations. In addition, while the value of the program has been accepted by the
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funding body and participating sites on the basis of previous rollouts and grey literature reports [9,18],
this study is expected to provide a platform for adoption of the DCHP across each State in Australia.
Such an outcome requires robust evidence of clinical benefit and cost effectiveness, particularly as
Australia is a federated democracy where acute hospital care is the responsibility of individual States.
The order of implementation is not randomized. While randomization would be preferable,
with only four sites this is not critical. In addition, introducing significant change in hospitals
requires hospital ownership of the program, which is facilitated by a negotiated start date reflecting
organizational readiness.
This evaluation will measure the hospital-acquired complication rate in a large prospective
cohort of older Australian hospital patients with and without CI. The international literature on
hospital-acquired complication rates in patients with dementia has been based on retrospective
data [31], which is known to be incomplete and potentially missing half the at-risk group [3].
New international studies are prospective but smaller in terms of sample sizes [32]. Real-time capture
of data on all older patients with CI in hospital may have the effect of either decreasing or increasing
the recorded hospital-acquired complication rate. We hypothesize that patients with mild symptoms,
who are possibly missed in retrospective studies, are at greater risk because they receive no or little
support beyond that given for their documented comorbidities. Therefore the risk rate will be higher.
It is possible that this assumption is incorrect and the complications are rather a reflection of the degree
of CI, resulting in a reduced complication rate reflecting milder CI.
As CI, which may include delirium, is the inclusion criterion, and delirium is an outcome measure,
there is a risk that the impact of the DCHP on delirium may be confounded. Delirium, as an outcome
measure in this study, would require staff to have not recorded it as a problem when the CI screening
was completed, but to have recorded it at a later stage. As this would suggest an escalation in the
symptomology on at least a behavioral level, a factor on which the DCHP impacts, it was decided that
the retention of delirium as an outcome measure is methodologically sound.
The impact of the DCHP on hospital-acquired complications will be influenced by how
successfully the program is embedded into the hospital system. Measurement of changing carer
satisfaction, change in staff practice and awareness, and patient quality of life will act as surrogate
markers of individual hospital program adoption.
4. Limitations
The CI screening tools will not be consistent across all sites. It is possible, therefore, that the
population identified as at risk of hospital-acquired complications will vary across participating
hospitals. This variation will be mitigated by pooling the results across all four sites. The sensitivity
and specificity values of the screening tools used at the four sites are similar (AMT4 ; sensitivity 80%
and specificity 76% [33]; AMTS; sensitivity 81% specificity 84% [34]; MiniCog; sensitivity 76% and
specificity 73% [35]). The Clock Drawing Test [23] was used in addition to some screening tools as
it has previously been found to increase the sensitivity and specificity of other screening tests [36].
As there are a wide variety of CI screening tools used in Australia, the variance in tool use reflects
real practice.
Equally, while there is relative consistency of data extraction methodology, in Australia there is
variance in how hospital events are recorded. This may also impact on the final data.
The target number of positive screens for CI was estimated from national data and experience
from previous rollouts of the DCHP in Victoria. If the number of positive screens is significantly fewer
than the predicted number, this could impact on the statistical power of the study.
While there were no exclusions within the target recruitment population, it is likely that universal
screening of all patients 65+ in a hospital environment will not be achieved. The results will be reported
on an intention-to-treat basis. This is a conservative approach but is likely to reflect real-world practice,
so a positive result is more likely to translate across hospitals.
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The DEMQoL [25,26] was not originally designed for use in the hospital setting. It is expected
that there may be a significant number of patients who may not be able to complete the survey because
of ill-health.
The National Commission on Safety and Quality in Health Care has released advice relating to
screening for CI in acute care, and the screening for, and management of, delirium (ACSQHC 2013).
As this advice will be taken up at the state level gradually, there may be some impact on screening
practice that is not attributable to implementation of the DCHP which should be mitigated by the
study design.
5. Conclusions
This is the first large multi-site prospective trial to evaluate the impact of a program to detect and
manage cognitive impairment in the acute hospital setting.
6. Patents
The CII is a registered trademark held by Ballarat Health Services. This has been done to protect
its integrity and appropriate usage. Licensing is free to Australian health services.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-4601/15/9/1878/s1.
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